PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. is a company founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D. and Thomas Shenk, Ph.D. It describes itself as building a precision oncology platform that leverages more than four decades of research experience and unique insights into the p53 protein, aiming to selectively target mutant p53 and provide therapies for patients whose tumors harbor these gene mutations. Its pipeline includes rezatapopt, and it has announced public offerings of securities.

PMV Pharmaceuticals was founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D. and Thomas Shenk, Ph.D. The company states that over the past ten years it has built a precision oncology platform that leverages more than four decades of research experience and unique insights into the p53 protein. It has assembled a management team of biopharmaceutical experts with extensive experience in oncology drug discovery and development. Its pipeline includes rezatapopt, and it has announced public offerings of securities.

Precision oncology platform selectively targeting mutant p53

• rezatapopt

  Listed in the PMV Pipeline.

• 2020.09.25

  Reported2020.09.25

  PMV Pharmaceuticals prices IPO at $18 per share[4]PMV Pharmaceuticals将IPO发行价定为每股18美元finanznachrichten.de

  PMV Pharmaceuticals announced pricing its initial public offering of 11.765 million common shares at $18 per share. The company said the shares were to begin trading on Nasdaq Global Select Market on September 25, 2020, and expected the offering to close on September 29, 2020.

• 2019.11.13

  Reported2019.11.13

  PMV Pharma completes $62 million Series C financing[5]PMV Pharma完成6200万美元C轮融资prweb.com

  PMV Pharmaceuticals announced completion of a $62 million Series C financing round led by Nextech Invest, with participation from other new and existing investors. The proceeds will support development of the company's p53 drug candidates.

Read more

1. 1PMV Pharma | Harnessing the Power of p53 to treat Cancerpmvpharma.com
2. 2Management | Harnessing the Power of p53 to treat Cancer | PMV Pharmapmvpharma.com
3. 3Science | Harnessing the Power of p53 to Treat Cancer | PMV Pharmapmvpharma.com
4. 4PMV Pharmaceuticals将IPO发行价定为每股18美元finanznachrichten.de
5. 5PMV Pharma完成6200万美元C轮融资prweb.com